Search articles by title, topic or section.
Khabre desk
Recent reporting, analysis and explainers from the melanoma desk.
health
A pooled analysis of two early-stage trials reported objective responses in 10 of 15 patients with advanced melanoma treated with the investigational TIL therapy amsoki-cel at its recommended dose. The small, non-randomized analysis also found frequent severe blood-related side effects, while a larger trial cohort is ongoing.
health
A prespecified five-year analysis of RELATIVITY-047 found lower hazards of progression and death with relatlimab plus nivolumab than with nivolumab alone. Exploratory biomarker analyses also linked higher LAG-3-positive CD8 cell levels to worse outcomes on nivolumab in a defined subgroup.
health
A bioRxiv preprint reports four genomic subtypes of mucosal melanoma and immune-cell patterns associated with disease progression and immunotherapy resistance. The findings point to TIM-3 as a possible research target, not an established treatment.
health
A pooled analysis of 1,038 patients found 86.5% five-year overall survival after neoadjuvant immune checkpoint inhibitors for resectable melanoma. Among patients whose tumours had a major pathological response, estimated five-year survival was 98%.
health
A bioRxiv preprint uses spatial multi-omics and 3D imaging to map melanoma tumours treated with neoadjuvant immunotherapy. The study links organised immune structures, including tertiary lymphoid structures and germinal centres, with treatment response and disease-free survival.